Citius Oncology (CTOR) Current Assets (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Current Assets data on file, last reported at $29.4 million in Q1 2026.

• On a quarterly basis, Current Assets rose 63.11% year-over-year to $29.4 million in Q1 2026; TTM through Mar 2026 was $29.4 million, a 63.11% increase from a year earlier, with the FY2025 full-year figure at $27.5 million, up 151.1% from the prior year.
• Current Assets for Q1 2026 stood at $29.4 million, down from $37.1 million in the prior quarter.
• Over the last five years, Current Assets for CTOR reached as high as $37.1 million in Q4 2025 and fell as low as $40988.0 in Q2 2024.
• Historically, Current Assets has averaged $12.0 million across 5 years, with a median of $9.4 million in 2023.
• Across the five-year window, Current Assets sank 91.13% in 2024 and jumped 44569.36% in 2025, its largest moves.
• Year by year, Current Assets stood at $377344.0 in 2022, then sank by 84.58% to $58200.0 in 2023, then jumped by 29249.62% to $17.1 million in 2024, then soared by 117.47% to $37.1 million in 2025, then fell by 20.79% to $29.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $29.4 million in Q1 2026, $37.1 million in Q4 2025, and $27.5 million in Q3 2025.